Investors’ deep pessimism is actually bullish, and less regulatory constraint could fuel new drug approvals and M&A.

Of late, pharmaceutical behemoth Pfizer Inc.’s PFE stock has struggled, but it remains a bargain with generous dividends. Its ...

Not content with a $1.2 billion licensing deal for Biohaven Pharma's oral migraine therapy rimegepant, Pfizer has just offered to buy the company outright – for a cool $11.6 billion. Pfizer's ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Following Pfizer's acquisition, Biohaven's valuation surged from $300M at $7/share to over $4B at $42/share under Vlad Coric's leadership. Despite the significant valuation increase, substantial ...

Pfizer's stock has recently struggled but remains a bargain with generous dividends. Is now a good time to invest in PFE?

Pfizer subsidiary Biohaven allegedly gave physicians speaker honoraria and meals at high-end restaurants to induce them to prescribe Nurtec. Healthcare lease accounting insights: How two organizations ...

November 25, 2024 Biohaven's spinal muscular atrophy drug ... data allayed investor worries following a setback last year. Pfizer explores options for some rare disease, cancer drugs Pfizer ...

Pfizer anunció que comprará el fabricante de medicamentos para la migraña Biohaven por alrededor de $ 11.6 mil millones, en efectivo.